Drug intelligence / Profile preview

acyclovir

Development stage
Approved
Lead developer
GSK
Modality
Small Molecules
Administration
Oral, Intravenous, Topical, Ophthalmic, Buccal
01

Overview

**Acyclovir** is a synthetic guanine nucleoside analogue antiviral drug originally developed by GSK and widely available as branded and generic products. It is selectively activated in herpesvirus-infected cells by viral thymidine kinase and subsequently converted by host enzymes to acyclovir triphosphate. The active metabolite competitively inhibits herpesvirus DNA polymerase and causes viral DNA-chain termination, suppressing replication of herpes simplex virus type 1, herpes simplex virus type 2, and varicella-zoster virus. It is used systemically and topically for herpes simplex infections, genital herpes, herpes zoster, varicella, herpes labialis, severe mucocutaneous herpesvirus infection in immunocompromised patients, and severe invasive HSV disease including HSV encephalitis and neonatal herpes. ([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0910335b-6796-459f-b97e-d7ef5439a060))

Brand names
ZoviraxSitavig
Other names
aciclovirACVacycloguanosine9-[(2-hydroxyethoxy)methyl]guanine阿昔洛韦
02

Targets

Herpesvirus DNA polymerase

Beyond the preview

Go deeper on acyclovir.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on acyclovir.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call